Kisspeptin-10

What Kisspeptin-10 does

Kisspeptin-10 triggers reproductive hormone release, but home injection benefits and long-term safety remain unproven. Libido and IVF findings for kisspeptin-54 do not establish benefits for kisspeptin-10. Small studies found hormone changes, sometimes including testosterone. A 2026 study tested under-skin infusions for up to 12 days in healthy men. It has no approved dose.

• In small studies in men, an IV dose raised testosterone and LH, the hormone that signals the testes. (Studied in a trial)
• In a small study, pump doses under the skin kept their hormone effect for 12 days. (Studied in a trial)
• Studied as a test of the brain's reproductive signal in delayed puberty and low sex hormone conditions. (Studied in a trial)
• People report stronger libido or fuller testes, but no one confirmed it with tests. (Reported by users)

Uses in the sources

• Studied as a probe of GnRH function in hypogonadism and delayed puberty. Some congenital cases do not respond. (Studied in a trial) (source)
• Studied for hormone stimulation in high prolactin, PCOS and low testosterone with type 2 diabetes. Clinical benefits remain unproven. (Studied in a trial) (source)
• Used online for libido and as a proposed hCG alternative during TRT. Improved fertility or sexual function has not been established for KP-10. (Reported by users) (source)
• Investigated for oxytocin and vasopressin diagnostic testing; this does not establish a treatment for either deficiency. (Studied in a trial) (source)

Kisspeptin-10 dosage

Typical reported dose: 100–200 mcg once a day

• Single IV pulse: 0.24 nmol/kg IV once one bolus, into a vein. Studied in a trial. Studied in: 13 healthy adult men. (source)
• IV dose-finding arms: 0.01, 0.03, 0.1, 0.3, 1 or 3 mcg/kg IV once one bolus per separate visit, into a vein. Studied in a trial. Studied in: Healthy men; n=6 for boluses and n=4 in each infusion experiment. (source)
• 22.5-hour IV infusion: 3 mcg/kg IV bolus; 90 minutes later, 4 mcg/kg/h IV for 22.5 hours continuous infusion per hour, into a vein. Studied in a trial. Studied in: Healthy men; n=6 for boluses and n=4 in each infusion experiment. (source)
• 9-hour IV infusion: 1.5 mcg/kg/h IV for 9 hours continuous infusion per hour, into a vein. Studied in a trial. Studied in: Healthy men; n=6 for boluses and n=4 in each infusion experiment. (source)
• IV bolus arms by sex: Men: 0.3, 1, 3 or 10 nmol/kg. Follicular women: 1, 3 or 10; preovulatory women: 10 nmol/kg. one bolus per study visit, into a vein. Studied in a trial. Studied in: 11 healthy men and 35 healthy women; 4–5 per dose group. (source)
• Single SC dose-finding arms: 2, 4, 8, 16 or 32 nmol/kg SC once one bolus per study visit, under the skin. Studied in a trial. Studied in: Healthy women in the follicular phase. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix Kisspeptin-10

Comes as: Community: freeze-dried powder vials, Research: controlled IV solution or SC pump infusion, FDA review: compounded injections and troches, without an approved label.

Mixed with: Community reports describe bacteriostatic water; clinical studies used controlled saline-based preparations. These are separate practices..

Common vial sizes: 10 mg. Common water amounts: 1, 2, 3 mL.

• Forum reports describe 10 mg vials with 1, 2 or 3 mL water; these are reported choices, not validated formulations.
• Gelling was reported after 10 mg with 2 mL bacteriostatic water. Do not treat a changed or cloudy product as a usable solution.
• No evidence supports rescuing a gelled vial by adding acid at home.
• Clinical study handling and vial checks cannot be transferred to an unidentified online powder.

Before mixing: Community posters describe freezing dry vials. No validated shelf life was found for an unidentified vial; formulation and packaging matter.

After mixing: Community reports use refrigeration. No validated home-use expiry or sterility period was found; a clear vial is not proof of sterility.

Kisspeptin-10 side effects and risks

Reported side effects

• Headache: 5/21 IV and 2/15 SC in the hyperprolactinemia registry; consented denominators, not causal rates., mild. Trial severity grades were not posted; persistent or marked symptoms need review. (source)
• Skin pain: 3/21 IV and 2/15 SC; 4/9 versus 4/9 placebo had other skin events in the glucose registry., mild. Trial severity grades were not posted; persistent or marked symptoms need review. (source)
• Fatigue: 2/21 IV versus 0/15 SC in the prolactin registry; 1/9 KP 10 versus 1/9 placebo in the glucose study., mild. Trial severity grades were not posted; persistent or marked symptoms need review. (source)
• Nausea or dizziness: SC prolactin arm: nausea 1/15 and dizziness 1/15; IV dizziness 1/21. Causality unknown., mild. Trial severity grades were not posted; persistent or marked symptoms need review. (source)
• Irregular periods: 2/9 KP 10 versus 1/9 placebo in the glucose registry. Reports do not establish drug causality., moderate. Trial severity grades were not posted; persistent or marked symptoms need review. (source)
• Muscle breakdown: serious event report: 1/18 consented participants in NCT04648969, after study visits ended; only 7 completed dosing. Causality unknown., serious (source)
• Allergic or immune reaction: No reliable KP 10 incidence; FDA flags possible immune reactions from aggregates or impurities., serious (source)
• Weight gain and higher estrone: One incomplete FAERS report after 100 mcg SC daily for 6 weeks; not a proven drug effect., moderate (source)

Stop and get help if

• Trouble breathing, throat swelling, widespread hives or fainting after injection: Stop and seek emergency care now.
• Chest pain, sudden weakness, severe breathlessness or collapse: Seek emergency care now; do not wait for hormone tests.
• Severe muscle pain or weakness with dark urine: Seek urgent care for possible muscle breakdown.
• Fever with worsening redness, swelling or pus at an injection site: Stop injections and get prompt care for possible infection.

Who should avoid it

• pregnant: Precaution: pregnancy safety has not been established; KP-10 affects reproductive signaling.
• breastfeeding: Precaution: milk transfer and infant safety are unknown.
• tryingToConceive: Keep fertility use within a specialist plan; ovulation effects vary and a home conception schedule is unproven.
• under18: Research includes children, but no approved pediatric treatment or home dose exists.
• hormoneSensitiveCancer: Precaution: reproductive hormone stimulation may conflict with cancer care; no human cancer-safety data establish acceptability.
• activeCancer: Cancer effects vary by cell model. Human cancer safety is unknown; review any active cancer with the oncology team.
• heartCondition: KP-10 contracts isolated vessels and worsened plaque in susceptible mice. Human cardiovascular risk is unknown.
• uncontrolledBloodPressure: Vessel-contraction findings support caution; acute small trials cannot establish safety in uncontrolled hypertension.
• diabetes: A small diabetes study measured hormones, not diabetes outcomes. Glucose and medication effects need review.
• kidneyDisease: No validated kidney-function dose adjustment or repeated-dose safety data were found.
• liverDisease: No validated liver-function dose adjustment or repeated-dose safety data were found.
• testedAthlete: WADA 2026 S2.2.1 names kisspeptin under testosterone-stimulating peptides in males; prohibited at all times.
• other: Avoid re-exposure after a severe reaction to this peptide or its injection ingredients.
• other: Unexplained low testosterone, high prolactin or absent periods can signal pituitary disease; establish the cause before hormone manipulation.

Interactions

• Testosterone and anabolic androgens: Androgen feedback may blunt the upstream response. KP-10 has not been shown to preserve sperm production during testosterone use.
• Estrogen, progestogens and hormonal contraception: Sex steroids change the LH response. No evidence shows that KP-10 makes contraception fail.
• Other kisspeptins or receptor agonists: Duplicate pathway stimulation has no established combined home dose; prolonged exposure can reduce the hormonal response.
• GnRH drugs and fertility hormones: These act on the same reproductive axis. Research combinations require a set protocol; effects on ovulation and hormone levels may change.
• Insulin and sulfonylureas: No established KP-10 interaction or excess low-blood-sugar rate. Review glucose medicines because metabolic effects remain under study.

Product quality risks

• One analytical study tested one illicit KP-10 vial: no unexpected impurities were found, but it was more degraded than the reference standard.
• One vial cannot establish market-wide purity, correct amount, sterility or endotoxin safety.
• FDA flags aggregates, peptide impurities and immune-response risks in injectable KP-10.
• Health Canada has seized unauthorized KP-10 injections; contamination, wrong ingredients and infection are concerns.

What to expect

Early studies in healthy men tested single IV doses or infusions lasting up to 22.5 hours, rather than multiweek home-injection cycles.

38 human research records include ongoing studies and studies without results; some share participants. Most measured short-term hormones, not lasting benefits or long-term safety.

Key studies

• A bolus resets LH timing: One IV dose triggered an LH pulse and delayed the next spontaneous pulse. (source)
• First dose and infusion study: IV dosing raised LH and testosterone; these experiments did not test home injection schedules. (source)
• Response depends on sex and cycle: KP-10 cleared in minutes; women responded differently across the cycle. (source)
• Cycle phase changes the LH response: Responses to the same dose varied by menstrual phase. (source)
• Contraception changes the response: Combined-pill users had a blunted LH response. (source)
• NKB-deficient patients respond to infusion: Continuous KP-10 restored LH pulses in four selected patients. (source)

Kisspeptin-10 FAQ

• Is Kisspeptin-10 FDA-approved? No. PCAC voted 0 yes, 11 no on October 29, 2024. This was advisory, not an approval or final rule. No FDA-approved KP-10 label was found.
• How do people take it? Under the skin, once daily. Source: reported by users, not an established dose.
• What's the difference between Kisspeptin-10 and Gonadorelin? Kisspeptin-10: a short-acting experimental peptide that triggers reproductive hormone release. Gonadorelin: a short-acting fertility hormone used in tests and specialist pump therapy. Why people pair them: reported with KP-10 during TRT to support reproductive signaling. The home combination is untested.
• Can I take it with Gonadorelin? Reported with KP-10 during TRT to support reproductive signaling. The home combination is untested. Duplicate stimulation of the same axis; no established combined dose. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). The S2.2.1 restriction applies to male athletes. The ingredient, formulation and athlete-specific therapeutic use exemption must be checked with the antidoping authority.
• How long does a mixed vial last? Community reports use refrigeration. No validated home-use expiry or sterility period was found; a clear vial is not proof of sterility.